Investor directory

K2 HealthVentures

K2 HealthVentures is an alternative investment firm focused on providing flexible, long-term financing solutions to innovative private and public companies in the life sciences and healthcare industries. The investment team is comprised of collaborative, experienced professionals with diverse backgrounds in finance and operations, as well as deep domain knowledge across various healthcare sectors. A uniquely flexible, permanent capital structure enables the firm to provide creative, adaptive financing solutions and meet the evolving capital needs of its portfolio companies as they grow. K2HV is driven by dual goals of Profit and Purpose – aiming to fuel the growth of innovative companies that will ultimately improve the lives of patients and giving a percentage of investment profits back to underserved areas in healthcare.

Focus

BiotechnologyTherapeuticsSeries BMid VentureHealthcare and BiotechShow more
http://www.k2healthventures.com
https://k2healthventures.com
https://crunchbase.com/organization/k2-healthventures
https://linkedin.com/company/k2healthventures
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=601984023

Derek W. Abel

VP

Anup Arora

Founding MD and CIO

Isaiah Einzig

VP

Anthony Perry

Associate

Ben Porter

Senior Associate

Jack Roscoe

Associate

Nimesh Shah

MD

Parag Shah

Founding MD and CEO

Austin Sherwindt

Principal

Ken Tang

Principal

Mark Winter

Associate

19 past transactions

Vesta Healthcare

Venture Round in 2021
Vesta Healthcare develops health care technology platform to connect caregiver to the care team. The company provides 24/7 telehealth support for caregivers and care recipients. It partners with home care agencies, health plans, and providers to develop value-based population health programs. Vesta Healthcare was formerly known as Hometeam Technologies, Inc. and changed its name to Vesta Healthcare in January 2020. The company was incorporated in 2008 and is based in New York, New York.

Inari

Debt Financing in 2020
Inari Agriculture, Inc. develops customized seeds to grow crop using CRISPR gene editing technology. The technology helps crops grow in local conditions such as humidity, temperatures, and soil types. The company uses the technology on seeds such as wheat, soya bean, and corn. Inari Agriculture, Inc. was formerly known as VL40, Inc. The company was incorporated in 2016 and is based in Cambridge, Massachusetts.

Oncorus

Post in 2022
Oncorus, Inc. is a lean early-stage biotechnology company developing a next-generation immunotherapy platform to treat cancer. Oncorus was founded MPM Managing Director Mitch Finer, a well-known biotechnology entrepreneur. Oncorus is a leader in corporate philanthropy, and has taken a pledge to donate a portion of product sales to fund promising cancer research and to support cancer care in the developing world.

VBI Vaccines

Post in 2020
VBI Vaccines is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. VBI’s eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines that closely mimic the target virus. VBI is headquartered in Cambridge, MA with research facilities in Ottawa, Canada.

ASLAN Pharmaceuticals

Debt Financing in 2021
ASLAN Pharmaceuticals Limited, a clinical-stage immunology and oncology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company’s clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and a small molecule inhibitor targeting oncology. Its partners include Almirall, Array BioPharma, Bristol-Myers Squibb, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.

Companion Medical

Debt Financing in 2020
Companion Medical develops products to improve healthcare with easy-to-use medical devices that utilize state-of-the-art technologies. It has experience in medical devices and critical systems development, and its team is positioned to introduce exciting new medical products that improve and facilitate patient care. The company’s initial products focus on providing improved care to insulin using Diabetics.

TScan Therapeutics

Debt Financing in 2022
TScan Therapeutics is an experienced group of scientists, development specialists, and other leaders driving a cutting edge platform. TScan Therapeutics is an owner and operator of a biotechnology company intended to develop immunotherapy treatments for cancer. The company identifies T-cell targets in a genome-wide high-throughput manner, expanding the treatment of immuno-oncology to patients who have few therapeutic options. TScan Therapeutics is harnessing novel T cell systems to extend the promise of immunotherapy. The company is dedicated to changing lives by discovering new cancer targets and developing safe and effective T-cell therapies for patients.

VBI Vaccines

Post in 2022
VBI Vaccines is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. VBI’s eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines that closely mimic the target virus. VBI is headquartered in Cambridge, MA with research facilities in Ottawa, Canada.

Cricket Health

Series B in 2021
Cricket Health is a specialty kidney care provider of integrated nephrology and dialysis care for people with Chronic Kidney Disease (CKD) and End Stage Renal Disease (ESRD). Cricket Health delivers world-class, technology-enabled multidisciplinary care both in-person and virtually to achieve the best outcomes possible for patients and the best value for partners, keeping patients healthy and out of the hospital, accelerating access to transplant, and increasing home dialysis adoption. We are committed to aligning the success of our company with those of our partners and the patients whom we serve. Learn more at www.crickethealth.com and follow us @crickethealth

VBI Vaccines

Post in 2021
VBI Vaccines is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. VBI’s eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines that closely mimic the target virus. VBI is headquartered in Cambridge, MA with research facilities in Ottawa, Canada.

Invaio Sciences

Debt Financing in 2021
Invaio Sciences, Inc. is a Flagship Pioneering Company startup in Cambridge. They are at the forefront of developing novel technologies based on groundbreaking science with an intent to positively impact their planet by enabling the application of breakthrough solutions in agriculture, human health, animal nutrition and animal health.

Colorescience

Debt Financing in 2020
Colorescience, Inc. produces and sells mineral-based cosmetics and sun screen products. It offers treatment products, UV protectors, primers, foundations, and enhancers. The company’s products are used to treat pigmentation, redness, dark circles, and aging problems, as well as sensitive, oily, and dry skin. It sells its products through a network of licensed physicians and luxury spas, retailers, and distributors; as well as online. The company was founded in 2000 and is based in Carlsbad, California. Colorescience, Inc. is a former subsidiary of SkinMedica, Inc.

Aptinyx

Post in 2021
Aptinyx Inc. is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication. This mechanism has applicability across a number of CNS disorders. Our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need.

Molecular Templates

Post in 2020
Molecular Templates Inc. (MTI) is a biopharmaceutical company with a novel protein platform for the development of new therapeutics against cancer. The company has a lead compound for melanoma that is expected to enter into clinical trials in the next two years and is developing additional compounds against a variety of other cancers.

Click Therapeutics

Series B in 2021
Click Therapeutics, Inc. engineers, validates, develops, and commercializes digital therapeutics solutions to benefit people with unmet medical needs through cognitive and neurobehavioral modification. It develops and commercializes novel digital therapeutics for various indications, including smoking cessation, major depressive disorders, schizophrenia, insomnia, acute coronary syndrome, migraine, overactive bladder, chronic low back pain, and obesity. Click Therapeutics, Inc. was founded in 2012 and is based in New York, New York.

Metacrine

Debt Financing in 2019
Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities.

Surface Oncology

Private Placement in 2019
Surface Oncology was created to advance next-generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno-biology. Together with world-leading scientific founders, the Company is advancing multiple preclinical programs that target novel mechanisms shown to play vital roles in tumor immune-evasion. Surface is based in Cambridge, Mass.

Platelet BioGenesis

Series B in 2021
Platelet BioGenesis, Inc. operates as a biotechnology company that produces commercial scale donor-independent human platelets from pluripotent stem cells for clinical application. The company develops a microfluidic bioreactor, which includes generation of functional platelets from human stem cell cultures at scale. It distributes bioreactor platelets to hospitals and blood banks to give to patients worldwide. The company was founded in 2014 and is based in Cambridge, Massachusetts.

Click Therapeutics

Debt Financing in 2020
Click Therapeutics, Inc. engineers, validates, develops, and commercializes digital therapeutics solutions to benefit people with unmet medical needs through cognitive and neurobehavioral modification. It develops and commercializes novel digital therapeutics for various indications, including smoking cessation, major depressive disorders, schizophrenia, insomnia, acute coronary syndrome, migraine, overactive bladder, chronic low back pain, and obesity. Click Therapeutics, Inc. was founded in 2012 and is based in New York, New York.